Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
Stefan D. Anker(Bayer (Germany)), Milton Packer(Baylor University Medical Center), Michael Böhm(Saarland University), Martina Brueckmann, Piotr Ponikowski(Wroclaw Medical University), Nikolaus Marx(RWTH Aachen University), Javed Butler(Jackson Memorial Hospital), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), Sergio V. Perrone(Inserm), Sven Schnaidt(Inserm), Anne Pernille Ofstad(Boehringer Ingelheim (Norway)), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), James L. Januzzi(Harvard University), Muhammad Shahzeb Khan(University of Mississippi Medical Center), Carolyn S.P. Lam(University of Glasgow), Subodh Verma(St. Michael's Hospital), João Pedro Ferreira(Inserm), E A Bocchi(Universidade de São Paulo), Waheed Jamal(Inserm)
Cited by 350
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k